 Eton Pharmaceuticals Inc NASDAQ: ETON has sold its neurology portfolio that includes lamotrigine ET-105, zonisamide ET-104, and topiramate ET-101 product candidates, to Azurity Pharmaceuticals. The marketing applications for all three candidates are currently under review with the FDA. 